WILMINGTON, NC (WECT) – A new drug may soon be on the market to combat breast cancer if the FDA gives its approval.
The experimental drug called Iniparib is being used in clinical trials at Duke.
[Learn more about the drug (HTML)]
The drug helps shrink tumors in women with triple-negative breast cancer. This type of breast cancer lacks receptors for estrogen and progesterone, so drugs like Tamoxifen don't work.
Researchers say Iniparib not only shrinks tumors, it significantly prolongs a woman's survival.